The Duo P201 Trial will evaluate the safety and immune response of 4 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
Streptococcus pneumoniae is a common type of bacteria (germ) that can cause a wide variety of diseases, ranging from mild sinus and ear infections to more serious infections of the lungs, lining of the brain, or blood that require hospitalization and can be life-threatening. While anyone can get pneumococcal disease, adults over 50 have a higher risk of experiencing severe illness and are 8 times more likely to be hospitalized with pneumococcal pneumonia than younger adults.
According to the Centers for Disease Control and Prevention (CDC), getting vaccinated is the best way to help protect against pneumococcal disease. The CDC recommends that adults 65 years of age and older receive a pneumococcal vaccine as part of their routine vaccinations.
The vaccines available today protect against many strains of pneumococcal bacteria, but not all of them. That’s why we thought you may be interested in learning about Pfizer’s pneumococcal vaccine clinical trial designed to broaden protection against more bacterial strains.
We’re currently enrolling people who are:
- 50 to 64 years of age and have not previously received a pneumococcal vaccine.
- 65 years of age or older and have either not received a pneumococcal vaccine or have received the PNEUMOVAX® 23 vaccine more than 5 years ago.
Taking part in this clinical trial could potentially improve vaccine protection not only for you, but also others in the future.
Interested in joining this study? Here’s what you can expect if you take part:
- The study will last about one year, and you will attend at least 4 study visits.
- You will be randomly assigned to receive one dose of either the study vaccine or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®). You have an equal chance of being assigned to either vaccine group. There is no placebo (a shot with no active ingredient) in this study.
- Your safety is always our top priority. Our medical team will closely monitor your health while you are in the study. You can also leave this clinical trial at any time and for any reason.
- There is no cost to participate, and health insurance is not required. You will also be paid for completing study-related activities.
Please contact our team for more information. We’ll review the study’s requirements with you to help you decide if this clinical trial is a good fit for you.
Learn more about our COVID-19 vaccine study for healthy adults and adolescents 12 years and older.
Did you know that flu viruses change every year? That’s why yearly vaccination is the most effective way to help prevent flu and its complications.
mRNA vaccines are changing the way we fight seasonal illnesses. Learn more about Pfizer’s research to help improve flu vaccines using mRNA technology.
C. diff is a leading cause of infectious diarrhea in adults 65 and older that can result in severe illness and recurrent symptoms. Learn about Pfizer’s new vaccine study which may help to protect against C. diff infection.
This clinical trial’s purpose is to test a new study drug, called AZD0780. The study drug is a small molecule PCSK9 inhibitor that aims to lower the levels of “bad cholesterol” in the blood.
Volunteers who join the trial will take AZD0780(study drug) orally, every day for 12 weeks, which is about three months. Your participation in the study will help to determine the
effectiveness, safety, and tolerability of AZD0780(study drug) and how it affects LDL-C (bad cholesterol) levels and levels of other types of fat in your blood.
You may qualify if you:
- Are male or female of non-childbearing potential within an age range from 18 to 75 years.
- Fasting LDL-C levels (bad cholesterol): Between 70mg/dL (1.8 mmol/L) and < 190 mg/dL (4.9 mmol/L).
- Fasting triglycerides: < 400 mg/dL (< 4.52 mmol/L).
- Are receiving moderate or high-intensity statin therapy as per ACC/AHA (at least 2 months prior to screening).
- Body mass index (BMI): ≥ 19.0 kg/m2.
- Are capable of providing signed informed consent and comply with study requirements.
Contact us for more information: 786-772-0510
Evaluate the safety and effectiveness of quadrivalent influenza mRNA vaccines (QIV mRNA) compared to standard influenza vaccines. The study aims to assess safety profiles, describe immune responses, and guide future vaccine development.
Active-controlled study to assess the efficacy, safety, and tolerability of investigational drug Baxdrostat in combination with Dapagliflozin compared with Dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.
Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria.
Providing a community-based service and reliable data making possible the advances in the field of Investigational Research for new and better drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)